文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

英国COVID-19第一波与第二波疫情中接受静脉-静脉体外膜氧合治疗患者的长期结局比较

A Comparison of Long-Term Outcomes in Patients Managed With Venovenous Extracorporeal Membrane Oxygenation in the First and Second Waves of the COVID-19 Pandemic in the United Kingdom.
PubMed 文献 · Crit Care Med · 2023-04-05
一句话结论英国单中心回顾性队列显示,COVID-19第二波疫情中接受静脉-静脉ECMO治疗的患者拔管存活率(70.0% vs 90.4%)显著低于第一波,作者认为ECMO对经过严格筛选的COVID-19患者仍有持续作用。

该单中心回顾性队列研究比较了英国COVID-19第一波(2020年3月17日至2020年8月31日)与第二波(2020年1月9日至2021年5月25日)接受静脉-静脉ECMO治疗患者的急性期与随访结局,共纳入123例。第二波患者拔管存活率(90.4% vs 70.0%;p<0.001)及删失日期(2021年11月30日)存活率(χ²=6.35;p=0.012)显著低于第一波,ECMO运行时间更长(12.0 d [18.0-30.0 d] vs 29.5 d [15.5-58.3 d];p=0.005,原文此处数值表述有矛盾,照录)。第二波患者ECMO前无创通气时间更长、气压伤发生率更高。年龄与无创通气使用与死亡率独立相关(OR 1.07 [1.01-1.14];p=0.025 和 OR 3.37 [1.12-12.60];p=0.043)。随访时两波间生活质量及除血红蛋白校正的CO转移系数外的肺功能相似。作者认为ECMO对经过严格筛选的COVID-19患者仍有持续作用。

要点

  • 第二波拔管存活率显著低于第一波(90.4% vs 70.0%;p<0.001)。
  • 第二波删失日期(2021年11月30日)存活率显著低于第一波(χ²=6.35;p=0.012)。
  • 第二波ECMO运行时间更长(12.0 d [18.0-30.0 d] vs 29.5 d [15.5-58.3 d];p=0.005,原文数值表述有矛盾,照录)。
  • 年龄(OR 1.07 [1.01-1.14];p=0.025)与无创通气使用(OR 3.37 [1.12-12.60];p=0.043)与死亡率独立相关。
  • 随访时两波生活质量及除血红蛋白校正的CO转移系数外的肺功能相似。

适用人群与场景

  • 英国一家严重急性呼吸衰竭服务中心重症监护科收治的COVID-19并接受静脉-静脉ECMO治疗的患者。
  • 第一波:2020年3月17日至2020年8月31日;第二波:2020年1月9日至2021年5月25日(原文如此)。

研究设计与关键结果

  • 研究类型:单中心回顾性队列研究;共纳入123例。
  • 主要终点:第二波拔管存活率显著低于第一波(90.4% vs 70.0%;p<0.001);删失日期(2021年11月30日)存活率第二波显著低于第一波(χ²=6.35;p=0.012)。
  • 第二波ECMO运行时间更长(12.0 d [18.0-30.0 d] vs 29.5 d [15.5-58.3 d];p=0.005,原文数值表述有矛盾,照录)。
  • 第二波患者ECMO前无创通气应用时间更长,气压伤频率更高。
  • 年龄与无创通气使用与死亡率独立相关(OR 1.07 [1.01-1.14];p=0.025 和 OR 3.37 [1.12-12.60];p=0.043)。
  • 随访时两波间生活质量(欧洲五维三级版本量表)及除血红蛋白校正的CO转移系数外的肺功能相似。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:原文未报告局限性(原文为Retrospective single-center cohort study,但未在局限性段落中报告具体局限)。

对床旁实践的改变

  • 作者认为,ECMO对经过严格筛选的COVID-19患者仍有持续作用。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Early studies of venovenous extracorporeal membrane oxygenation (ECMO) in COVID-19 have revealed similar outcomes to historical cohorts. Changes in the disease and treatments have led to differences in the patients supported on venovenous ECMO in the first and second waves. We aimed to compare these two groups in both the acute and follow-up phase.

DESIGN: Retrospective single-center cohort study comparing mortality at censoring date (November 30, 2021) and decannulation, patient characteristics, complications and lung function and quality of life (QOL-by European Quality of Life 5 Dimensions 3 Level Version) at first follow-up in patients supported on venovenous ECMO between wave 1 and wave 2 of the COVID-19 pandemic.

SETTING: Critical care department of a severe acute respiratory failure service.

PATIENTS: Patients supported on ECMO for COVID-19 between wave 1 (March 17, 2020, to August 31, 2020) and wave 2 (January 9, 2020, to May 25, 2021).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: One hundred twenty-three patients were included in our analysis. Survival at censoring date (χ 2 , 6.35; p = 0.012) and decannulation (90.4% vs 70.0%; p < 0.001) was significantly lower in the second wave, while duration of ECMO run was longer (12.0 d [18.0-30.0 d] vs 29.5 d [15.5-58.3 d]; p = 0.005). Wave 2 patients had longer application of noninvasive ventilation (NIV) prior to ECMO and a higher frequency of barotrauma. Patient age and NIV use were independently associated with increased mortality (odds ratio 1.07 [1.01-1.14]; p = 0.025 and 3.37 [1.12-12.60]; p = 0.043, respectively). QOL and lung function apart from transfer coefficient of carbon monoxide corrected for hemoglobin was similar at follow-up across the waves.

CONCLUSIONS: Most patients with COVID-19 supported on ECMO in both waves survived in the short and longer term. At follow-up patients had similar lung function and QOL across the two waves. This suggests that ECMO has an ongoing role in the management of a carefully selected group of patients with COVID-19.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Garfield BE, Bianchi P, Arachchillage DJ, et al. A Comparison of Long-Term Outcomes in Patients Managed With Venovenous Extracorporeal Membrane Oxygenation in the First and Second Waves of the COVID-19 Pandemic in the United Kingdom. Crit Care Med. 2023. PMID: 37276353. doi:10.1097/CCM.0000000000005864

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。